Single User License
INR 101235
Site License
INR 202470
Corporate User License
INR 303705

Service Tax Additional

select a format
Price

Single User License
USD 1500
Site License
USD 3000
Corporate User License
USD 4500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Gilead Sciences, Inc.-Product Pipeline Review-2015

Gilead Sciences, Inc.-Product Pipeline Review-2015


  Request for Sample Report

Executive Summary

Gilead Sciences, Inc.-Product Pipeline Review-2015

Summary

Global Markets Direct's, 'Gilead Sciences, Inc.-Product Pipeline Review-2015', provides an overview of the Gilead Sciences, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Gilead Sciences, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides brief overview of Gilead Sciences, Inc. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Gilead Sciences, Inc.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Gilead Sciences, Inc.'s pipeline products

Reasons To Buy

Evaluate Gilead Sciences, Inc.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Gilead Sciences, Inc. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Gilead Sciences, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Gilead Sciences, Inc. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Gilead Sciences, Inc.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Gilead Sciences, Inc. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Gilead Sciences, Inc. Snapshot 6

Gilead Sciences, Inc. Overview 6

Key Information 6

Key Facts 6

Gilead Sciences, Inc.-Research and Development Overview 7

Key Therapeutic Areas 7

Gilead Sciences, Inc.-Pipeline Review 13

Pipeline Products by Stage of Development 13

Pipeline Products-Monotherapy 14

Pipeline Products-Combination Treatment Modalities 15

Pipeline Products-Partnered Products 16

Pipeline Products-Out-Licensed Products 18

Gilead Sciences, Inc.-Pipeline Products Glance 20

Gilead Sciences, Inc.-Late Stage Pipeline Products 20

Gilead Sciences, Inc.-Clinical Stage Pipeline Products 22

Gilead Sciences, Inc.-Early Stage Pipeline Products 25

Gilead Sciences, Inc.-Drug Profiles 27

(elvitegravir + cobicistat + emtricitabine + tenofovir alafenamide) 27

(emtricitabine + tenofovir alafenamide) 29

(ledipasvir + sofosbuvir) 30

(emtricitabine + rilpivirine hydrochloride + tenofovir alafenamide) 33

(sofosbuvir + GS-5816) 34

ambrisentan 36

GS-6615 38

idelalisib 39

momelotinib dihydrochloride 42

ranolazine ER 45

tenofovir alafenamide 47

(GS-9857 + GS-5816 + sofosbuvir) 49

(ranolazine hydrochloride + dronedarone hydrochloride) 50

acalisib 51

GS-4774 52

GS-4997 53

GS-5745 54

GS-9256 55

GS-9620 56

GS-9669 58

GS-9973 59

ONO-4059 60

presatovir 62

Px-102 63

Px-104 64

regadenoson 66

simtuzumab 68

vedroprevir 70

GS-5829 71

GS-6637 72

GS-9857 73

GS-9883 74

GS-9901 75

velpatasvir 76

AB-0045 77

GS-548202 78

GS-5759 79

GS-607601 80

GS-8374 81

GS-967 82

Monoclonal Antibodies 1 for Cancer 83

Px-103 84

Small Molecule to Inhibit Histone Deacetylation for Cancer 85

Small Molecule to Inhibit Histone Methyltransferase for Cancer 86

GS-563253 87

GS-599220 88

Monoclonal Antibody for HIV / AIDS 89

Small Molecule to Inhibit NS4B Protein for HCV 90

Small Molecules to Inhibit NS3 Protease for Hepatitis C 91

Gilead Sciences, Inc.-Pipeline Analysis 92

Gilead Sciences, Inc.-Pipeline Products by Target 92

Gilead Sciences, Inc.-Pipeline Products by Route of Administration 94

Gilead Sciences, Inc.-Pipeline Products by Molecule Type 95

Gilead Sciences, Inc.-Pipeline Products by Mechanism of Action 96

Gilead Sciences, Inc.-Recent Pipeline Updates 98

Gilead Sciences, Inc.-Dormant Projects 122

Gilead Sciences, Inc.-Discontinued Pipeline Products 123

Discontinued Pipeline Product Profiles 123

Gilead Sciences, Inc.-Company Statement 127

Gilead Sciences, Inc.-Locations And Subsidiaries 132

Head Office 132

Other Locations & Subsidiaries 132

Appendix 138

Methodology 138

Coverage 138

Secondary Research 138

Primary Research 138

Expert Panel Validation 138

Contact Us 138

Disclaimer 139

List of Tables

Gilead Sciences, Inc., Key Information 9

Gilead Sciences, Inc., Key Facts 9

Gilead Sciences, Inc.-Pipeline by Indication, 2015 12

Gilead Sciences, Inc.-Pipeline by Stage of Development, 2015 16

Gilead Sciences, Inc.-Monotherapy Products in Pipeline, 2015 17

Gilead Sciences, Inc.-Combination Treatment Modalities in Pipeline, 2015 18

Gilead Sciences, Inc.-Partnered Products in Pipeline, 2015 19

Gilead Sciences, Inc.-Partnered Products/ Combination Treatment Modalities, 2015 20

Gilead Sciences, Inc.-Out-Licensed Products in Pipeline, 2015 21

Gilead Sciences, Inc.-Out-Licensed Products/ Combination Treatment Modalities, 2015 22

Gilead Sciences, Inc.-Pre-Registration, 2015 23

Gilead Sciences, Inc.-Phase III, 2015 24

Gilead Sciences, Inc.-Phase II, 2015 25

Gilead Sciences, Inc.-Phase I, 2015 27

Gilead Sciences, Inc.-Preclinical, 2015 28

Gilead Sciences, Inc.-Discovery, 2015 29

Gilead Sciences, Inc.-Pipeline by Target, 2015 95

Gilead Sciences, Inc.-Pipeline by Route of Administration, 2015 97

Gilead Sciences, Inc.-Pipeline by Molecule Type, 2015 98

Gilead Sciences, Inc.-Pipeline Products by Mechanism of Action, 2015 99

Gilead Sciences, Inc.-Recent Pipeline Updates, 2015 101

Gilead Sciences, Inc.-Dormant Developmental Projects,2015 125

Gilead Sciences, Inc.-Discontinued Pipeline Products, 2015 126

Gilead Sciences, Inc., Other Locations 135

Gilead Sciences, Inc., Subsidiaries 136

List of Figures

Gilead Sciences, Inc.-Pipeline by Top 10 Indication, 2015 11

Gilead Sciences, Inc.-Pipeline by Stage of Development, 2015 16

Gilead Sciences, Inc.-Monotherapy Products in Pipeline, 2015 17

Gilead Sciences, Inc.-Combination Treatment Modalities in Pipeline, 2015 18

Gilead Sciences, Inc.-Partnered Products in Pipeline, 2015 19

Gilead Sciences, Inc.-Out-Licensed Products in Pipeline, 2015 21

Gilead Sciences, Inc.-Pipeline by Top 10 Target, 2015 95

Gilead Sciences, Inc.-Pipeline by Top 10 Route of Administration, 2015 97

Gilead Sciences, Inc.-Pipeline by Top 10 Molecule Type, 2015 98

Gilead Sciences, Inc.-Pipeline Products by Top 10 Mechanism of Action, 2015 99

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Current R&D Portfolio of Gilead Sciences, Inc.; Gilead Sciences, Inc. - Key Therapeutics; Gilead Sciences, Inc. - Pipeline Overview and Promising Molecules; Gilead Sciences, Inc. - News; Gilead Sciences, Inc. - Latest Updates; Gilead Sciences, Inc. - Pipeline; Gilead Sciences, Inc. - Discontinued/Dormant Projects


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com